Identification
- Summary
Fenspiride is an oxazolidinone spiro compound with antispasmodic and bronchodilator effects used in the treatment of ENT and respiratory diseases.
- Generic Name
- Fenspiride
- DrugBank Accession Number
- DB08979
- Background
Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Fenspiride (DB08979)
- Weight
- Average: 260.3315
Monoisotopic: 260.152477894 - Chemical Formula
- C15H20N2O2
- Synonyms
- Fenspirida
- Fenspiride
- Fenspiridum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Allergic rhinitis (ar) •••••••••••• ••••• Symptomatic treatment of Bronchial asthma •••••••••••• ••••• Symptomatic treatment of Bronchitis •••••••••••• ••••• Symptomatic treatment of Coughing •••••••••••• ••••• Symptomatic treatment of Flu caused by influenza •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Fenspiride hydrochloride 832NBX878V 5053-08-7 FIKFLLIUPUVONI-UHFFFAOYSA-N
Categories
- ATC Codes
- R03BX01 — Fenspiride
- R03BX — Other drugs for obstructive airway diseases, inhalants
- R03B — OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azaspirodecane derivatives
- Sub Class
- Not Available
- Direct Parent
- Azaspirodecane derivatives
- Alternative Parents
- Phenethylamines / Aralkylamines / Piperidines / Oxazolidinones / Carbamate esters / Trialkylamines / Organic carbonic acids and derivatives / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds show 3 more
- Substituents
- Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azaspirodecane / Benzenoid / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Hydrocarbon derivative show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S983QC7HKM
- CAS number
- 5053-06-5
- InChI Key
- FVNFBBAOMBJTST-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)
- IUPAC Name
- 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
- SMILES
- O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1
References
- Synthesis Reference
U.S. Patent 3,399,192.
- General References
- Not Available
- External Links
- PubChem Compound
- 3344
- PubChem Substance
- 310264940
- ChemSpider
- 3227
- 4335
- ChEBI
- 94558
- ChEMBL
- CHEMBL576127
- ZINC
- ZINC000000001441
- Wikipedia
- Fenspiride
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suppository Capsule 40 MG Syrup Syrup 0.8 % Syrup 2 mg/ml Pill - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 232-233 U.S. Patent 3,399,192. - Predicted Properties
Property Value Source Water Solubility 2.75 mg/mL ALOGPS logP 1.42 ALOGPS logP 1.6 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 13.29 Chemaxon pKa (Strongest Basic) 8.97 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 41.57 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 73.73 m3·mol-1 Chemaxon Polarizability 29.14 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-02dm-6900000000-c5c47109f1891f3cfda9 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0090000000-2a9733da0d1c486d69bf Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0090000000-4d46b81a8d1afd18960e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-08fr-0590000000-acb64266ba822d9b3062 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9170000000-edc48dfaaea0751d9c21 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-3930000000-06b234e2278a7dac1400 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000g-1910000000-b68b7b30e164391e4bfb Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 160.43921 predictedDeepCCS 1.0 (2019) [M+H]+ 162.79723 predictedDeepCCS 1.0 (2019) [M+Na]+ 169.35289 predictedDeepCCS 1.0 (2019)
Drug created at June 10, 2014 15:23 / Updated at June 02, 2021 20:03